About ThermoGenesis

ThermoGenesis is a product-focused company founded on disciplined science and engineering capabilities. We thrive on addressing customer needs for unique solutions to challenging medical questions. Our advanced technical capabilities integrate cell biology with device engineering to harness complex science into practical tools for the researcher and clinician.

Founded in 1986 with pioneering cryopreservation technology, ThermoGenesis has extended its product and service offerings in the adult stem cell industry to include cell processing and therapeutic systems. Thermogenesis offers automated and semi-automated devices, and single-use processing disposables that enable the collection, processing, and cryopreservation of stem cells and other cellular tissues from cord blood and bone marrow used in the practice of regenerative medicine. Our understanding and enthusiasm for the emerging regenerative medicine segment positions us for a leadership role by providing best-in-class products to this exciting global market.

Our purpose is to enable healthcare providers, researchers, and patients to prevail over serious diseases through our relentless efforts to discover, develop and deliver innovative technologies and products in the dynamic regenerative medicine field. We intend to build value for our investors and employees through the strength of our customers’ satisfaction and by consistently producing superior operating results.

Markets

ThermoGenesis manufactures and sells laboratory and point-of-care products for the preparation of adult stem cell products from various tissue sources. The cell output of our products is used in diverse research and for therapeutic purposes by licensed personnel around the world.

ThermoGenesis markets its products into the broad regenerative medicine segment, one of the most dynamic, exciting and fast growing areas of modern healthcare. The potential therapeutic benefits of stem cells, whether allogeneic and autologous (a donor’s or one’s own cells, respectively), tissue engineering, and composite tissue transplants offer significant market opportunities. The developments in directed immune-suppression, tissue scaffold and device combinations, and expansion of new master cell lines create the need for supporting tools and workflow processes to optimize their production and preservation. All are significant market opportunities in their own right to expedite recovery from traumatic injury, potentially curb or reverse chronic disease, and generally improve quality of life for affected patients.
Business Development

ThermoGenesis holds intellectual property addressing cell processing devices and methodologies. It has deep experience and capabilities in relevant device engineering, regulatory processes, cell biology and cell process workflow. We currently apply these combined intellectual assets to the development of new and useful technologies and products in adult stem cell and platelet production.

ThermoGenesis is actively seeking incremental development opportunities through licensing, joint development and commercialization relationships with entities with complementary capabilities and vision. We intend to expand our offerings across the broad regenerative medicine field and are receptive to new dialogue regarding interesting intellectual property, product development and market focused ventures.

For more information about ThermoGenesis Corp. please visit our website at www.thermogenesis.com or phone 916-858-5107